Rene Bernards - 30 Jun 2024 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role: Director
Signature: /s/ Rene Bernards
Issuer symbol: LIXT
Transactions as of: 30 Jun 2024
Net transactions value: $0
Form type: 4
Filing time: 05 Jul 2024, 16:16:41 UTC
Previous filing: 05 Oct 2023
Next filing: 29 Oct 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LIXT	Options to Purchase Common Stock	Award	$0	+10,000		$0.000000	10,000	30 Jun 2024	Common	10,000	$2.37	Direct	F1
transaction	LIXT	Options to Purchase Common Stock	Award	$0	+4,149		$0.000000	4,149	30 Jun 2024	Common	4,149	$2.37	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Effective June 30,2024, the reporting person was granted stock options to purchase an aggregate of 10,000 shares, vesting on the last day of each subsequent quarter until fully vested (i.e. vesting to start on September 30,2024). The grant was (a) in lieu of cash compensation to which the reporting person was otherwise entitled to receive under his previous agreement with the Company which has been amended as July 3,2024 to provide for the grant of stock options to replace the payment of cash; and (b) pursuant to the annual grant under the Company's amended Compensation Plan applicable to the Company's non-officer directors.
F2	Effective June 30, 2024, the reporting person was granted stock options to purchase an aggregate of 4,149 shares vesting immediately. The grant was (a) in lieu of cash compensation due to the reporting person pursuant to his previous agreement with the Company referenced in Footnote 1; and (b) pursuant to the quarterly grant under the Company's amended Compensation Plan applicable to the Company's non-officer directors.

Content

Effective June 30,2024, the reporting person was granted stock options to purchase an aggregate of 10,000 shares, vesting on the last day of each subsequent quarter until fully vested (i.e. vesting to start on September 30,2024). The grant was (a) in lieu of cash compensation to which the reporting person was otherwise entitled to receive under his previous agreement with the Company which has been amended as July 3,2024 to provide for the grant of stock options to replace the payment of cash; and (b) pursuant to the annual grant under the Company's amended Compensation Plan applicable to the Company's non-officer directors.

Effective June 30, 2024, the reporting person was granted stock options to purchase an aggregate of 4,149 shares vesting immediately. The grant was (a) in lieu of cash compensation due to the reporting person pursuant to his previous agreement with the Company referenced in Footnote 1; and (b) pursuant to the quarterly grant under the Company's amended Compensation Plan applicable to the Company's non-officer directors.